Antiphospholipid Antibodies Differ in aPL Cofactor Requirement

Although autoimmune antiphospholipid antibodies (aPL) may require a serum cofactor, beta2-glycoprotein I (β2GPI), for maximal binding in aPL ELISA, it is not known whether cofactor is absolutely required or is merely an enhancing factor for binding, nor is it clear whether aPL bind to cofactor itsel...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lupus 1992-02, Vol.1 (2), p.83-90
Hauptverfasser: Sammaritano, Lisa R., Lockshin, Michael D., Gharavi, Azzudin E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although autoimmune antiphospholipid antibodies (aPL) may require a serum cofactor, beta2-glycoprotein I (β2GPI), for maximal binding in aPL ELISA, it is not known whether cofactor is absolutely required or is merely an enhancing factor for binding, nor is it clear whether aPL bind to cofactor itself, a cofactor-lipid complex, or a phospholipid modified in some way by cofactor. We therefore isolated and purified β2GPI and evaluated its relationship to both IgG and IgM aPL binding. aPL derived from different sera appear to have differing requirements for cofactor; the proportion of total binding attributable to cofactor varies from 46% to 95%. aPL do not bind to β 2GPI in the absence of phospholipid. Enhanced binding to phospholipid is seen if β2GPI is provided either before or with the test antibody. Autoimmune aPL bind phospholipid better with human rather than bovine cofactor. The requirement for cofactor is greater for low-avidity aPL as measured in an IgG-human cofactor system. Cofactor requirement alone does not predict the presence or absence of associated clinical complications.
ISSN:0961-2033
1477-0962
DOI:10.1177/096120339200100205